Fortitude Biomedicines is a private biotechnology company pioneering next-generation biologics that combine precise immune-cell targeting with molecular glue payloads to create more effective antibody-drug conjugates. Its proprietary GLUE-DACTM discovery engine, originating from research at Baylor College of Medicine, integrates ADC precision with targeted protein degradation to widen therapeutic windows, overcome resistance, and unlock new drug targets. The company’s lead immune-cell-targeting biologic is being advanced through IND-enabling studies, funded by its recently secured seed capital. Beyond this flagship candidate, Fortitude is building a broader pipeline aimed at oncology and autoimmune indications using the GLUE-DACTM platform. Headquartered in Waltham, Massachusetts, Fortitude was co-founded by serial entrepreneur Jesse Chen, Ph.D., and Baylor College of Medicine professor Jin Wang, Ph.D.; Chen now serves as president and CEO. The business is still pre-revenue and focused on preclinical research, with future milestones centered on submitting its first IND and expanding its ADC portfolio.

Total raised

$13M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026